Barley β-glucan increases fecal bile acid excretion and short chain fatty acid levels in mildly hypercholesterolemic individuals
The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms such as gut fermentation, inhibition of intestinal cholesterol absorption and increased bile acid excretion and its synthesis. However, one of t...
Saved in:
| Published in | Food & function Vol. 9; no. 6; pp. 392 - 396 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Royal Society of Chemistry
20.06.2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms such as gut fermentation, inhibition of intestinal cholesterol absorption and increased bile acid excretion and its synthesis. However, one of the recent studies from our laboratory indicated that increased bile acid excretion and subsequent increase in its synthesis, but not the inhibition of cholesterol absorption or synthesis might be responsible for the cholesterol-lowering effect of barley β-glucan. Accordingly, the primary objective of the present study was to investigate the concentration of bile acids (BA), neutral sterols (NS) and short chain fatty acids (SCFA) excreted through the feces by mildly hypercholesterolemic subjects who consumed diets containing barley β-glucan with varying molecular weights (MW) and concentrations. In a controlled, four phase, crossover trial, 30 mildly hypercholesterolemic but otherwise healthy subjects were randomly assigned to receive breakfast containing 3 g high MW (HMW), 5 g low MW (LMW), 3 g LMW barley β-glucan or a control diet for 5 weeks. The concentrations of BA, NS and SCFA in the feces were measured at the end of each treatment phase. Compared to the other treatment groups, 3 g day
−1
HMW barley β-glucan consumption resulted in increased lithocholic acid (LCA) excretion (
P
< 0.001) but not LMW β-glucan, even at the high dose of 5 g day
−1
. Increased fermentability of fibre was also evident from a significant increase in fecal total SCFA concentrations in response to the 3 g HMW β-glucan diet compared to the 3 g LMW barley β-glucan and control diet (
P
= 0.0015). In summary, the current results validate our previous report on the role of fecal bile acid excretion in cholesterol lowering through the consumption of barley β-glucan. In addition, increased SCFA concentrations indicate that an increase in β-glucan molecular weight promotes hindgut fermentation, which might also be playing a role in attenuating cholesterol levels.
The specific objective of the human feeding trial was to elucidate the role of bile acids and short chain fatty acids in mediating cholesterol lowering effects of barley β-glucan. |
|---|---|
| AbstractList | The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms such as gut fermentation, inhibition of intestinal cholesterol absorption and increased bile acid excretion and its synthesis. However, one of the recent studies from our laboratory indicated that increased bile acid excretion and subsequent increase in its synthesis, but not the inhibition of cholesterol absorption or synthesis might be responsible for the cholesterol-lowering effect of barley β-glucan. Accordingly, the primary objective of the present study was to investigate the concentration of bile acids (BA), neutral sterols (NS) and short chain fatty acids (SCFA) excreted through the feces by mildly hypercholesterolemic subjects who consumed diets containing barley β-glucan with varying molecular weights (MW) and concentrations. In a controlled, four phase, crossover trial, 30 mildly hypercholesterolemic but otherwise healthy subjects were randomly assigned to receive breakfast containing 3 g high MW (HMW), 5 g low MW (LMW), 3 g LMW barley β-glucan or a control diet for 5 weeks. The concentrations of BA, NS and SCFA in the feces were measured at the end of each treatment phase. Compared to the other treatment groups, 3 g day
−1
HMW barley β-glucan consumption resulted in increased lithocholic acid (LCA) excretion (
P
< 0.001) but not LMW β-glucan, even at the high dose of 5 g day
−1
. Increased fermentability of fibre was also evident from a significant increase in fecal total SCFA concentrations in response to the 3 g HMW β-glucan diet compared to the 3 g LMW barley β-glucan and control diet (
P
= 0.0015). In summary, the current results validate our previous report on the role of fecal bile acid excretion in cholesterol lowering through the consumption of barley β-glucan. In addition, increased SCFA concentrations indicate that an increase in β-glucan molecular weight promotes hindgut fermentation, which might also be playing a role in attenuating cholesterol levels.
The specific objective of the human feeding trial was to elucidate the role of bile acids and short chain fatty acids in mediating cholesterol lowering effects of barley β-glucan. The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms such as gut fermentation, inhibition of intestinal cholesterol absorption and increased bile acid excretion and its synthesis. However, one of the recent studies from our laboratory indicated that increased bile acid excretion and subsequent increase in its synthesis, but not the inhibition of cholesterol absorption or synthesis might be responsible for the cholesterol-lowering effect of barley β-glucan. Accordingly, the primary objective of the present study was to investigate the concentration of bile acids (BA), neutral sterols (NS) and short chain fatty acids (SCFA) excreted through the feces by mildly hypercholesterolemic subjects who consumed diets containing barley β-glucan with varying molecular weights (MW) and concentrations. In a controlled, four phase, crossover trial, 30 mildly hypercholesterolemic but otherwise healthy subjects were randomly assigned to receive breakfast containing 3 g high MW (HMW), 5 g low MW (LMW), 3 g LMW barley β-glucan or a control diet for 5 weeks. The concentrations of BA, NS and SCFA in the feces were measured at the end of each treatment phase. Compared to the other treatment groups, 3 g day⁻¹ HMW barley β-glucan consumption resulted in increased lithocholic acid (LCA) excretion (P < 0.001) but not LMW β-glucan, even at the high dose of 5 g day⁻¹. Increased fermentability of fibre was also evident from a significant increase in fecal total SCFA concentrations in response to the 3 g HMW β-glucan diet compared to the 3 g LMW barley β-glucan and control diet (P = 0.0015). In summary, the current results validate our previous report on the role of fecal bile acid excretion in cholesterol lowering through the consumption of barley β-glucan. In addition, increased SCFA concentrations indicate that an increase in β-glucan molecular weight promotes hindgut fermentation, which might also be playing a role in attenuating cholesterol levels. The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms such as gut fermentation, inhibition of intestinal cholesterol absorption and increased bile acid excretion and its synthesis. However, one of the recent studies from our laboratory indicated that increased bile acid excretion and subsequent increase in its synthesis, but not the inhibition of cholesterol absorption or synthesis might be responsible for the cholesterol-lowering effect of barley β-glucan. Accordingly, the primary objective of the present study was to investigate the concentration of bile acids (BA), neutral sterols (NS) and short chain fatty acids (SCFA) excreted through the feces by mildly hypercholesterolemic subjects who consumed diets containing barley β-glucan with varying molecular weights (MW) and concentrations. In a controlled, four phase, crossover trial, 30 mildly hypercholesterolemic but otherwise healthy subjects were randomly assigned to receive breakfast containing 3 g high MW (HMW), 5 g low MW (LMW), 3 g LMW barley β-glucan or a control diet for 5 weeks. The concentrations of BA, NS and SCFA in the feces were measured at the end of each treatment phase. Compared to the other treatment groups, 3 g day −1 HMW barley β-glucan consumption resulted in increased lithocholic acid (LCA) excretion ( P < 0.001) but not LMW β-glucan, even at the high dose of 5 g day −1 . Increased fermentability of fibre was also evident from a significant increase in fecal total SCFA concentrations in response to the 3 g HMW β-glucan diet compared to the 3 g LMW barley β-glucan and control diet ( P = 0.0015). In summary, the current results validate our previous report on the role of fecal bile acid excretion in cholesterol lowering through the consumption of barley β-glucan. In addition, increased SCFA concentrations indicate that an increase in β-glucan molecular weight promotes hindgut fermentation, which might also be playing a role in attenuating cholesterol levels. The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms such as gut fermentation, inhibition of intestinal cholesterol absorption and increased bile acid excretion and its synthesis. However, one of the recent studies from our laboratory indicated that increased bile acid excretion and subsequent increase in its synthesis, but not the inhibition of cholesterol absorption or synthesis might be responsible for the cholesterol-lowering effect of barley β-glucan. Accordingly, the primary objective of the present study was to investigate the concentration of bile acids (BA), neutral sterols (NS) and short chain fatty acids (SCFA) excreted through the feces by mildly hypercholesterolemic subjects who consumed diets containing barley β-glucan with varying molecular weights (MW) and concentrations. In a controlled, four phase, crossover trial, 30 mildly hypercholesterolemic but otherwise healthy subjects were randomly assigned to receive breakfast containing 3 g high MW (HMW), 5 g low MW (LMW), 3 g LMW barley β-glucan or a control diet for 5 weeks. The concentrations of BA, NS and SCFA in the feces were measured at the end of each treatment phase. Compared to the other treatment groups, 3 g day-1 HMW barley β-glucan consumption resulted in increased lithocholic acid (LCA) excretion (P < 0.001) but not LMW β-glucan, even at the high dose of 5 g day-1. Increased fermentability of fibre was also evident from a significant increase in fecal total SCFA concentrations in response to the 3 g HMW β-glucan diet compared to the 3 g LMW barley β-glucan and control diet (P = 0.0015). In summary, the current results validate our previous report on the role of fecal bile acid excretion in cholesterol lowering through the consumption of barley β-glucan. In addition, increased SCFA concentrations indicate that an increase in β-glucan molecular weight promotes hindgut fermentation, which might also be playing a role in attenuating cholesterol levels. The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms such as gut fermentation, inhibition of intestinal cholesterol absorption and increased bile acid excretion and its synthesis. However, one of the recent studies from our laboratory indicated that increased bile acid excretion and subsequent increase in its synthesis, but not the inhibition of cholesterol absorption or synthesis might be responsible for the cholesterol-lowering effect of barley β-glucan. Accordingly, the primary objective of the present study was to investigate the concentration of bile acids (BA), neutral sterols (NS) and short chain fatty acids (SCFA) excreted through the feces by mildly hypercholesterolemic subjects who consumed diets containing barley β-glucan with varying molecular weights (MW) and concentrations. In a controlled, four phase, crossover trial, 30 mildly hypercholesterolemic but otherwise healthy subjects were randomly assigned to receive breakfast containing 3 g high MW (HMW), 5 g low MW (LMW), 3 g LMW barley β-glucan or a control diet for 5 weeks. The concentrations of BA, NS and SCFA in the feces were measured at the end of each treatment phase. Compared to the other treatment groups, 3 g day−1 HMW barley β-glucan consumption resulted in increased lithocholic acid (LCA) excretion (P < 0.001) but not LMW β-glucan, even at the high dose of 5 g day−1. Increased fermentability of fibre was also evident from a significant increase in fecal total SCFA concentrations in response to the 3 g HMW β-glucan diet compared to the 3 g LMW barley β-glucan and control diet (P = 0.0015). In summary, the current results validate our previous report on the role of fecal bile acid excretion in cholesterol lowering through the consumption of barley β-glucan. In addition, increased SCFA concentrations indicate that an increase in β-glucan molecular weight promotes hindgut fermentation, which might also be playing a role in attenuating cholesterol levels. The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms such as gut fermentation, inhibition of intestinal cholesterol absorption and increased bile acid excretion and its synthesis. However, one of the recent studies from our laboratory indicated that increased bile acid excretion and subsequent increase in its synthesis, but not the inhibition of cholesterol absorption or synthesis might be responsible for the cholesterol-lowering effect of barley β-glucan. Accordingly, the primary objective of the present study was to investigate the concentration of bile acids (BA), neutral sterols (NS) and short chain fatty acids (SCFA) excreted through the feces by mildly hypercholesterolemic subjects who consumed diets containing barley β-glucan with varying molecular weights (MW) and concentrations. In a controlled, four phase, crossover trial, 30 mildly hypercholesterolemic but otherwise healthy subjects were randomly assigned to receive breakfast containing 3 g high MW (HMW), 5 g low MW (LMW), 3 g LMW barley β-glucan or a control diet for 5 weeks. The concentrations of BA, NS and SCFA in the feces were measured at the end of each treatment phase. Compared to the other treatment groups, 3 g day-1 HMW barley β-glucan consumption resulted in increased lithocholic acid (LCA) excretion (P < 0.001) but not LMW β-glucan, even at the high dose of 5 g day-1. Increased fermentability of fibre was also evident from a significant increase in fecal total SCFA concentrations in response to the 3 g HMW β-glucan diet compared to the 3 g LMW barley β-glucan and control diet (P = 0.0015). In summary, the current results validate our previous report on the role of fecal bile acid excretion in cholesterol lowering through the consumption of barley β-glucan. In addition, increased SCFA concentrations indicate that an increase in β-glucan molecular weight promotes hindgut fermentation, which might also be playing a role in attenuating cholesterol levels.The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms such as gut fermentation, inhibition of intestinal cholesterol absorption and increased bile acid excretion and its synthesis. However, one of the recent studies from our laboratory indicated that increased bile acid excretion and subsequent increase in its synthesis, but not the inhibition of cholesterol absorption or synthesis might be responsible for the cholesterol-lowering effect of barley β-glucan. Accordingly, the primary objective of the present study was to investigate the concentration of bile acids (BA), neutral sterols (NS) and short chain fatty acids (SCFA) excreted through the feces by mildly hypercholesterolemic subjects who consumed diets containing barley β-glucan with varying molecular weights (MW) and concentrations. In a controlled, four phase, crossover trial, 30 mildly hypercholesterolemic but otherwise healthy subjects were randomly assigned to receive breakfast containing 3 g high MW (HMW), 5 g low MW (LMW), 3 g LMW barley β-glucan or a control diet for 5 weeks. The concentrations of BA, NS and SCFA in the feces were measured at the end of each treatment phase. Compared to the other treatment groups, 3 g day-1 HMW barley β-glucan consumption resulted in increased lithocholic acid (LCA) excretion (P < 0.001) but not LMW β-glucan, even at the high dose of 5 g day-1. Increased fermentability of fibre was also evident from a significant increase in fecal total SCFA concentrations in response to the 3 g HMW β-glucan diet compared to the 3 g LMW barley β-glucan and control diet (P = 0.0015). In summary, the current results validate our previous report on the role of fecal bile acid excretion in cholesterol lowering through the consumption of barley β-glucan. In addition, increased SCFA concentrations indicate that an increase in β-glucan molecular weight promotes hindgut fermentation, which might also be playing a role in attenuating cholesterol levels. |
| Author | Thandapilly, Sijo J Ndou, Saymore P Ames, Nancy P Wang, Yanan Nyachoti, Charles M |
| AuthorAffiliation | Department of Animal Science University of Manitoba Agriculture and Agri-Food Canada Richardson Center for Functional Foods and Nutraceuticals Human Nutritional Sciences |
| AuthorAffiliation_xml | – sequence: 0 name: Richardson Center for Functional Foods and Nutraceuticals – sequence: 0 name: Department of Animal Science – sequence: 0 name: University of Manitoba – sequence: 0 name: Human Nutritional Sciences – sequence: 0 name: Agriculture and Agri-Food Canada |
| Author_xml | – sequence: 1 givenname: Sijo J surname: Thandapilly fullname: Thandapilly, Sijo J – sequence: 2 givenname: Saymore P surname: Ndou fullname: Ndou, Saymore P – sequence: 3 givenname: Yanan surname: Wang fullname: Wang, Yanan – sequence: 4 givenname: Charles M surname: Nyachoti fullname: Nyachoti, Charles M – sequence: 5 givenname: Nancy P surname: Ames fullname: Ames, Nancy P |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29872803$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFks9qFTEUxoO02Fq7ca8E3IgweiaZP8lSL9a2FLpRcDckmRNvLpnMNZkpztJX8kF8JnO9bYUimM0XOL_zcU6-PCEHYQxIyLMS3pTA5Vsj7AhQ1u3mETlmULGiqeHLwd29ks0ROU1pA_lwKYUUj8kRk6JlAvgx-fFeRY8L_fWz-OpnowJ1wURUCRO1aJSn2nmkyrie4vdcmdwYqAo9TesxTtSslQvUqmla9pDHG_Qpu9DB-d4vdL1sMZr16DFNGLMMzuRy725cPyufnpJDmwVPb_WEfD778Gl1Xlxdf7xYvbsqDG9hKrCRUlmrUDOVV2HcCo2yt40Ca5Cbsqx1XVVYMYmtaKWobS-11q0GZYyW_IS82vtu4_htzsN0g0sGvVcBxzl1jDEQFYdW_B-FuoT8tHLn-vIBuhnnGPIiO6otQTZQZ-rFLTXrAftuG92g4tLd5ZCB13vAxDGliPYeKaHb5dytxNn1n5wvMwwPYOMmtQtmisr5f7c837fEZO6t_34d_huALLYh |
| CitedBy_id | crossref_primary_10_1016_j_cis_2019_102045 crossref_primary_10_1007_s10695_021_01028_2 crossref_primary_10_3390_foods12142693 crossref_primary_10_1080_10408398_2020_1864619 crossref_primary_10_3389_fcimb_2022_983027 crossref_primary_10_1016_j_foodchem_2020_128219 crossref_primary_10_1111_ijfs_14025 crossref_primary_10_1093_jas_sky398 crossref_primary_10_1021_acs_jafc_8b07306 crossref_primary_10_1016_S2468_1253_19_30257_2 crossref_primary_10_1016_j_foodchem_2022_132198 crossref_primary_10_1039_D2FO01167K crossref_primary_10_1016_j_jff_2022_105156 crossref_primary_10_1039_C9FO03009C crossref_primary_10_3390_molecules25081819 crossref_primary_10_2174_1381612825666190130101108 crossref_primary_10_1111_ijfs_14971 crossref_primary_10_1007_s12602_025_10465_x crossref_primary_10_1016_j_aquaculture_2019_734607 crossref_primary_10_1111_ijfs_17205 crossref_primary_10_1016_j_ijbiomac_2024_129435 crossref_primary_10_1002_mnfr_201900580 crossref_primary_10_3390_foods9020131 crossref_primary_10_1080_10408398_2022_2124231 crossref_primary_10_1016_j_foodchem_2022_132904 crossref_primary_10_3389_fmicb_2023_1083917 crossref_primary_10_1016_j_heliyon_2024_e38669 crossref_primary_10_3390_plants13172421 crossref_primary_10_1016_j_ijbiomac_2025_142025 crossref_primary_10_3389_fnut_2020_617676 crossref_primary_10_1016_j_bcdf_2024_100410 crossref_primary_10_1016_j_foodchem_2019_124973 crossref_primary_10_1017_S0007114520001610 crossref_primary_10_1016_j_clnu_2019_02_007 crossref_primary_10_1017_S0029665119000545 crossref_primary_10_1111_jfbc_13402 crossref_primary_10_3390_molecules26154559 crossref_primary_10_1016_j_fsi_2022_06_056 crossref_primary_10_1039_C8FO02507J crossref_primary_10_3390_ijms21186495 crossref_primary_10_1080_10408398_2021_1995842 crossref_primary_10_3390_jof6040356 crossref_primary_10_1111_jfbc_13680 crossref_primary_10_3390_nu14081570 crossref_primary_10_1007_s40495_019_00187_4 crossref_primary_10_1016_j_cofs_2022_100907 crossref_primary_10_1016_j_jpba_2020_113617 crossref_primary_10_1016_j_prmcm_2023_100300 crossref_primary_10_3390_nu13010130 crossref_primary_10_36660_abc_20210788 |
| Cites_doi | 10.1017/S0007114517002835 10.3945/jn.115.223206 10.3168/jds.S0022-0302(61)89956-6 10.1038/ejcn.2010.178 10.1016/j.jacl.2009.04.054 10.1194/jlr.R500013-JLR200 10.3390/ijms15023025 10.1017/S0007114510001030 10.1096/fj.201600465R 10.1017/S000711451600341X 10.1093/jn/120.7.668 10.1017/S0029665114001657 10.1001/jama.1991.03460140061027 10.1079/BJN19950124 10.1093/ajcn/56.1.99 10.1016/S0022-2275(20)33519-7 10.3389/fmicb.2016.00185 10.1038/nutd.2014.23 10.1155/2008/175285 10.1097/01.pap.0000249917.96509.e7 10.1093/ajcn/69.1.30 |
| ContentType | Journal Article |
| Copyright | Copyright Royal Society of Chemistry 2018 |
| Copyright_xml | – notice: Copyright Royal Society of Chemistry 2018 |
| DBID | AAYXX CITATION NPM 7T5 7T7 7TO 7U7 8FD C1K FR3 H94 P64 7X8 7S9 L.6 |
| DOI | 10.1039/c8fo00157j |
| DatabaseName | CrossRef PubMed Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Oncogenes and Growth Factors Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef PubMed Oncogenes and Growth Factors Abstracts Technology Research Database Toxicology Abstracts AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AGRICOLA CrossRef PubMed Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Diet & Clinical Nutrition |
| EISSN | 2042-650X |
| EndPage | 396 |
| ExternalDocumentID | 29872803 10_1039_C8FO00157J c8fo00157j |
| Genre | Journal Article |
| GroupedDBID | --- -JG 0-7 0R~ 4.4 53G 705 7~J AAEMU AAHBH AAIWI AAJAE AANOJ AARTK AAWGC AAXHV ABASK ABDVN ABEMK ABJNI ABPDG ABRYZ ABXOH ACGFS ACLDK ACPRK ADMRA ADSRN AEFDR AENEX AENGV AESAV AETIL AFLYV AFOGI AFRAH AFVBQ AGEGJ AGRSR AGSTE AHGCF AKBGW ALMA_UNASSIGNED_HOLDINGS ANUXI APEMP ASKNT AUDPV AZFZN BLAPV BSQNT C6K EBS ECGLT EE0 EF- EJD GGIMP H13 HZ~ H~N J3I O-G O9- P2P RAOCF RCNCU RNS RPMJG RRC RSCEA RVUXY SKF SKH SKJ SKM SKR SKZ SLC SLF AAYXX ABIQK ACRPL ADNMO AFRZK AGQPQ AHGXI AKMSF ALSGL ANBJS ANLMG ASPBG AVWKF CAG CITATION COF FEDTE HVGLF J3G J3H L-8 NPM 7T5 7T7 7TO 7U7 8FD C1K FR3 H94 P64 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c370t-e699affaeb2a00023f8be9df6a0fce3c115b544e429e787985fd9bbb7b0accb93 |
| ISSN | 2042-6496 2042-650X |
| IngestDate | Fri Jul 11 09:59:20 EDT 2025 Fri Jul 11 05:48:06 EDT 2025 Mon Jun 30 12:02:32 EDT 2025 Thu Apr 03 07:06:26 EDT 2025 Thu Apr 24 23:01:00 EDT 2025 Tue Jul 01 03:02:07 EDT 2025 Tue Dec 17 20:58:50 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c370t-e699affaeb2a00023f8be9df6a0fce3c115b544e429e787985fd9bbb7b0accb93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-9927-5191 |
| PMID | 29872803 |
| PQID | 2057109605 |
| PQPubID | 2047526 |
| PageCount | 5 |
| ParticipantIDs | pubmed_primary_29872803 crossref_primary_10_1039_C8FO00157J proquest_journals_2057109605 proquest_miscellaneous_2220843078 crossref_citationtrail_10_1039_C8FO00157J proquest_miscellaneous_2051064999 rsc_primary_c8fo00157j |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20180620 |
| PublicationDateYYYYMMDD | 2018-06-20 |
| PublicationDate_xml | – month: 6 year: 2018 text: 20180620 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Cambridge |
| PublicationTitle | Food & function |
| PublicationTitleAlternate | Food Funct |
| PublicationYear | 2018 |
| Publisher | Royal Society of Chemistry |
| Publisher_xml | – name: Royal Society of Chemistry |
| References | Chambers (C8FO00157J-(cit23)/*[position()=1]) 2015; 74 Nishina (C8FO00157J-(cit21)/*[position()=1]) 1990; 120 Wang (C8FO00157J-(cit7)/*[position()=1]) 2017; 118 Rios-Covian (C8FO00157J-(cit12)/*[position()=1]) 2016; 7 Chen (C8FO00157J-(cit6)/*[position()=1]) 2009; 3 Wang (C8FO00157J-(cit9)/*[position()=1]) 2016; 146 Ho (C8FO00157J-(cit4)/*[position()=1]) 2016; 116 Fernandes (C8FO00157J-(cit13)/*[position()=1]) 2014; 4 Batta (C8FO00157J-(cit16)/*[position()=1]) 1999; 40 Demigne (C8FO00157J-(cit22)/*[position()=1]) 1995; 74 Brown (C8FO00157J-(cit3)/*[position()=1]) 1999; 69 Davidson (C8FO00157J-(cit1)/*[position()=1]) 1991; 265 Arena (C8FO00157J-(cit19)/*[position()=1]) 2014; 15 Ridlon (C8FO00157J-(cit10)/*[position()=1]) 2006; 47 Erwin (C8FO00157J-(cit17)/*[position()=1]) 1961; 44 AbuMweis (C8FO00157J-(cit2)/*[position()=1]) 2010; 64 O'Toole (C8FO00157J-(cit20)/*[position()=1]) 2008; 2008 Wang (C8FO00157J-(cit15)/*[position()=1]) 2016; 7 Gunness (C8FO00157J-(cit18)/*[position()=1]) 2016; 30 Reyna-Villasmil (C8FO00157J-(cit5)/*[position()=1]) 2007; 14 Benus (C8FO00157J-(cit11)/*[position()=1]) 2010; 104 Zhang (C8FO00157J-(cit8)/*[position()=1]) 1992; 56 El Khoury (C8FO00157J-(cit14)/*[position()=1]) 2012; 2012 |
| References_xml | – volume: 118 start-page: 822 year: 2017 ident: C8FO00157J-(cit7)/*[position()=1] publication-title: Br. J. Nutr. doi: 10.1017/S0007114517002835 – volume: 146 start-page: 720 year: 2016 ident: C8FO00157J-(cit9)/*[position()=1] publication-title: J. Nutr. doi: 10.3945/jn.115.223206 – volume: 44 start-page: 1768 year: 1961 ident: C8FO00157J-(cit17)/*[position()=1] publication-title: J. Dairy Sci. doi: 10.3168/jds.S0022-0302(61)89956-6 – volume: 64 start-page: 1472 year: 2010 ident: C8FO00157J-(cit2)/*[position()=1] publication-title: Eur. J. Clin. Nutr. doi: 10.1038/ejcn.2010.178 – volume: 3 start-page: 154 year: 2009 ident: C8FO00157J-(cit6)/*[position()=1] publication-title: J. Clin. Lipidol. doi: 10.1016/j.jacl.2009.04.054 – volume: 47 start-page: 241 year: 2006 ident: C8FO00157J-(cit10)/*[position()=1] publication-title: J. Lipid Res. doi: 10.1194/jlr.R500013-JLR200 – volume: 15 start-page: 3025 year: 2014 ident: C8FO00157J-(cit19)/*[position()=1] publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms15023025 – volume: 104 start-page: 693 year: 2010 ident: C8FO00157J-(cit11)/*[position()=1] publication-title: Br. J. Nutr. doi: 10.1017/S0007114510001030 – volume: 30 start-page: 4227 year: 2016 ident: C8FO00157J-(cit18)/*[position()=1] publication-title: FASEB J. doi: 10.1096/fj.201600465R – volume: 2012 start-page: 851362 year: 2012 ident: C8FO00157J-(cit14)/*[position()=1] publication-title: J. Nutr. Metab. – volume: 116 start-page: 1369 year: 2016 ident: C8FO00157J-(cit4)/*[position()=1] publication-title: Br. J. Nutr. doi: 10.1017/S000711451600341X – volume: 120 start-page: 668 year: 1990 ident: C8FO00157J-(cit21)/*[position()=1] publication-title: J. Nutr. doi: 10.1093/jn/120.7.668 – volume: 74 start-page: 328 year: 2015 ident: C8FO00157J-(cit23)/*[position()=1] publication-title: Proc. Nutr. Soc. doi: 10.1017/S0029665114001657 – volume: 265 start-page: 1833 year: 1991 ident: C8FO00157J-(cit1)/*[position()=1] publication-title: JAMA doi: 10.1001/jama.1991.03460140061027 – volume: 7 start-page: 129 year: 2016 ident: C8FO00157J-(cit15)/*[position()=1] publication-title: Front. Microbiol. – volume: 74 start-page: 209 year: 1995 ident: C8FO00157J-(cit22)/*[position()=1] publication-title: Br. J. Nutr. doi: 10.1079/BJN19950124 – volume: 56 start-page: 99 year: 1992 ident: C8FO00157J-(cit8)/*[position()=1] publication-title: Am. J. Clin. Nutr. doi: 10.1093/ajcn/56.1.99 – volume: 40 start-page: 1148 year: 1999 ident: C8FO00157J-(cit16)/*[position()=1] publication-title: J. Lipid Res. doi: 10.1016/S0022-2275(20)33519-7 – volume: 7 start-page: 185 year: 2016 ident: C8FO00157J-(cit12)/*[position()=1] publication-title: Front. Microbiol. doi: 10.3389/fmicb.2016.00185 – volume: 4 start-page: e121 year: 2014 ident: C8FO00157J-(cit13)/*[position()=1] publication-title: Nutr. Diabetes doi: 10.1038/nutd.2014.23 – volume: 2008 start-page: 175285 year: 2008 ident: C8FO00157J-(cit20)/*[position()=1] publication-title: Interdiscip. Perspect. Infect. Dis. doi: 10.1155/2008/175285 – volume: 14 start-page: 203 year: 2007 ident: C8FO00157J-(cit5)/*[position()=1] publication-title: Am. J. Ther. doi: 10.1097/01.pap.0000249917.96509.e7 – volume: 69 start-page: 30 year: 1999 ident: C8FO00157J-(cit3)/*[position()=1] publication-title: Am. J. Clin. Nutr. doi: 10.1093/ajcn/69.1.30 |
| SSID | ssj0000399898 |
| Score | 2.396079 |
| Snippet | The cholesterol-lowering effect of barley β-glucan has been proposed to be the result of a pleiotropic effect, which involves several biological mechanisms... |
| SourceID | proquest pubmed crossref rsc |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 392 |
| SubjectTerms | Absorption Barley beta-glucans Bile Bile acids Biological effects breakfast Chains cholesteremic effect Cholesterol cross-over studies Diet Excretion Fatty acids Feces Fermentation Glucan Hindgut hypercholesterolemia intestinal absorption Intestine intestines lithocholic acid Molecular chains Molecular weight pleiotropy short chain fatty acids Sterols Synthesis β-Glucan |
| Title | Barley β-glucan increases fecal bile acid excretion and short chain fatty acid levels in mildly hypercholesterolemic individuals |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29872803 https://www.proquest.com/docview/2057109605 https://www.proquest.com/docview/2051064999 https://www.proquest.com/docview/2220843078 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZK98IL4jYIDGQEQ0JRRuqkafy4lpZpjO6BVitPUew4WqbSVr1IlDde-EH8EH4T5zjOBa1Cgxe3ciwryvlsf-f4XAh5lSqgHWEaOC0ZC8dPEuGEUgROnCjpu8ITnGO888dhcDL2TyftSaPxo-a1tFmLI_ltZ1zJ_0gV-kCuGCX7D5ItJ4UO-A_yhRYkDO2NZNzFq_KtfdjrH3aZ9j6P0XERieBKrexUoQAErHs7llliq68SYxaN__HqEpg3Bv5maOZYAxnXg6boRaSdZL9k02S6tS9BU13iJqlzKsAPetNnZRzXqk5vB5gjGcGEx2X9in-EBvp4kZnC1p-yq3l1ITVM5pvcOr1Ft98q5OzCGLM_x7MKxMMtFnjJvRCMs4Ax6RrjRStEJyvmVnscw-ggIImT-obMa7gL7MWR53LmQFPfaLGvdmgXT68dCK6H-VRlmM6RHXauqmOvuOofnkeD8dlZNOpPRrfIHgN1gzXJ3vGH7vuL0loH02ChTaxUWLxxkevW42-r6f9kN9dUFiAwy6KwjCYwo7vkjtE86HEOo3ukoWb3ifUuU2v6mpr0sFM6LKozPCDfc3jRXz8NtGgJLaqhRRFaFFFDS2hRkDPV0KIaWlRDKx-UQwtmoTm06C5o0Rq0HpLxoD_qnTimYocjvY67dlTAeZymsRIs1qmU0lAonqRB7KZSeRLUD9H2fQUkSMFJwcN2mnAhREe4sZSCe_ukOZvP1GNChRu4TCnQp0MFJBN2ElC1mR-kzOtwLlOLvCm-dCRNOnusqjKNtFuFx6NeODjXUjm1yMty7CJP4rJz1EEhsMgs8lXEQJ9poZrftsiL8jFswXivFs_UfKPHtIDZg6r1lzGMuaEPB2pokUc5GMpXYTzUReIssg_oKLsrVD25wbRPye1qgR2Q5nq5Uc-AL6_FcwPm31a7xug |
| linkProvider | Royal Society of Chemistry |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Barley+%CE%B2-glucan+increases+fecal+bile+acid+excretion+and+short+chain+fatty+acid+levels+in+mildly+hypercholesterolemic+individuals&rft.jtitle=Food+%26+function&rft.au=Thandapilly%2C+Sijo+J&rft.au=Ndou%2C+Saymore+P&rft.au=Wang%2C+Yanan&rft.au=Nyachoti%2C+Charles+M&rft.date=2018-06-20&rft.issn=2042-650X&rft.volume=9&rft.issue=6+p.3092-3096&rft.spage=3092&rft.epage=3096&rft_id=info:doi/10.1039%2Fc8fo00157j&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2042-6496&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2042-6496&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2042-6496&client=summon |